Healthpeak Raises 2026 Outlook, Authorizes $500M Buyback After Q2 Beat
DOC sits 38% above its 52-week low of $15.7.
Summary
Healthpeak delivered a solid Q2 with adjusted FFO of $0.46 per share, flat year-over-year but enough to prompt a $0.02 raise to the midpoint of full-year guidance. The new $500 million buyback authorization signals confidence, replacing the prior $100 million program. Leasing momentum is strong — 1.6 million square feet executed — and the balance sheet got a $1.4 billion boost from asset sales and recapitalizations. Janus Living continues to shine with 45% revenue growth. This follows the July sale of a 49% stake in an outpatient portfolio to Brookfield for over $1 billion, part of the capital recycling strategy. The raised guidance and buyback are incremental positives that should support the stock near its $22 consensus target.
At the time of this announcement, DOC was trading at $21.62 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $15.3B. The 52-week trading range was $15.70 to $22.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.